Management ChangeJul 15, 2026, 01:36 PM

Eupraxia Pharmaceuticals Announces Executive Leadership Changes

AI Summary

Eupraxia Pharmaceuticals announced updates to its executive leadership and operating structure on July 13, 2026, to prepare for its next stage of clinical and commercial development. Dr. Jeff Millard joined as Executive Vice President, Technical Operations, and Dr. Alex Therien took the helm of Research & Development. The company also transitioned its operations from Victoria to Vancouver and Seattle, with key executive positions, including the CEO, now based in Seattle. Amanda Malone stepped down from her role as Chief Scientific and Operating Officer.

Key Highlights

Dr. Jeff Millard joined Eupraxia as Executive Vice President, Technical Operations, effective July 13, 2026.
Dr. Alex Therien became Executive Vice President, Research & Development.
Company transitioned operations from Victoria to Vancouver and Seattle.
Key clinical, manufacturing, and commercial executive leadership positions, including the CEO, will be based in Seattle.
Amanda Malone stepped down as Chief Scientific and Operating Officer, effective July 10, 2026.

View SEC Filing

EPRX

Pharmaceuticals and Biotechnology

EUPRAXIA PHARMACEUTICALS INC.

Price Impact